Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 10/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18650807 | 0.79 | PIK3CD (0.35) | PIK3CD | |
| SCHEMBL21657462 | 0.77 | IDH1 (0.33) | IDH1 | |
| SCHEMBL22313305 | 0.75 | — | — | |
| SCHEMBL25100292 | 0.74 | IDH1 (0.39) | IDH1PIK3CD | |
| SCHEMBL10308853 | 0.72 | IDH1 (0.48) | IDH1 | |
| SCHEMBL10308855 | 0.72 | MTOR (0.31) | PIK3CD | |
| SCHEMBL12240400 | 0.70 | — | — | |
| SCHEMBL25099327 | 0.70 | CYP1A2 (0.31) | IDH1 | |
| SCHEMBL13379881 | 0.69 | PIK3CD (0.44) | IDH1PIK3CDKMT2A | |
| SCHEMBL15986199 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3397616-B1 | LSD1 INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2020-06-10 | — | — | EP | disclosed |
| US-10392375-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-08-27 | — | — | US | disclosed |
| US-10233152-B2 | LSD1 inhibitors | Mirati Therapeutics, Inc. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20180127369-A1 | LSD1 Inhibitors | Mirati Therapeutics, Inc. | 2018-05-10 | — | — | US | disclosed |
| US-20180127369-A1 | LSD1 Inhibitors | Mirati Therapeutics, Inc. | 2018-05-10 | — | — | US | disclosed |
| US-9809541-B2 | LSD1 inhibitors | Mirati Therapeutics, Inc. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9809541-B2 | LSD1 inhibitors | Mirati Therapeutics, Inc. (US) | 2017-11-07 | — | — | US | disclosed |
| WO-2017116558-A1 | LSD1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2017-07-06 | — | — | WO | disclosed |
| US-20170183308-A1 | LSD1 Inhibitors | Mirati Therapeutics, Inc. (US) | 2017-06-29 | — | — | US | disclosed |
| US-20170183308-A1 | LSD1 Inhibitors | Mirati Therapeutics, Inc. (US) | 2017-06-29 | — | — | US | disclosed |
| WO-2017079476-A1 | LSD1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2017-05-11 | — | — | WO | disclosed |
| US-20170129857-A1 | LSD1 Inhibitors | Mirati Therapeutics, Inc. (US) | 2017-05-11 | — | — | US | disclosed |
| US-20170081317-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10233152-B2 | LSD1 inhibitors | KDM1B, KDM1A, KDM3A | IDH1 120/4885PIK3CD 3138/4885MEN1 3225/4885 |
| US-20170129857-A1 | LSD1 Inhibitors | KDM1B, KDM1A, KDM3A | IDH1 120/4885PIK3CD 3138/4885MEN1 3225/4885 |
| US-20170183308-A1 | LSD1 Inhibitors | KDM1B, KDM1A, KDM3A | IDH1 120/4885PIK3CD 3138/4885MEN1 3225/4885 |
| US-20170081317-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | IDH1 1271/4885PIK3CD 137/4885MEN1 3661/4885 |
| US-10392375-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | IRAK2, IRAK3, IRAK1 | IDH1 1271/4885PIK3CD 137/4885MEN1 3661/4885 |
| US-20180127369-A1 | LSD1 Inhibitors | KDM1B, KDM1A, KDM3A | IDH1 120/4885PIK3CD 3138/4885MEN1 3225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.